Patients
Patients included in the trial met the following criteria: aged between 18 and 55 years; diagnosis of schizophrenia according to DSMâ€"fflâ€"R (American Psychiatric Asso ciation, 1987) disorganised (295.1) or resi dual (295.6) type; subchronic or chronic; two of Andreasen's negative components present to a marked degree and a score @ 60 on the SANS and @ 50 on the Scale for the Assessment of Positive Symptoms (SAPS; Andreasen, 1984b) . Patients presenting any other major DSM-.Iflâ€"Rdiagnosis, risk of suicide, alcohol or drug abuse, Parkinson's or any other severe somatic disease, or a prescription during the past six months of amisulpride for at least 30 days at a dose 01 < 400 mg/day were excluded.
Concomitant treatment

If needed for hypnotic or anxiolytic effect
only, oxazepam (up to 150 mg/day), bra zepam (up to 7.5 mg/day) or levomeproma zinc (up to SO mg/day) could be prescribed. Additional psychotherapy was not permitted.
Measures of efficacy and safety
The primary efficacy variables were the SANS, total score and subscores, and the CGI scale (National Institute of Mental Health, 1976a) . In addition, the SAPS and the Global Assessment of Functioning (GAF)
Background
Amisulpride isa substi tuted benzamidewith highselectivity for dopamine D2 and D3 receptors. The purpose of the study was to evaluate the effect of 00 mg amisulpride in patients with predominantly negativesymptomsof schizophrenia.
Method Thiswasamulti-centre, randomised,parallel-group, double-blind study.Patientsreceivedeither amisulpride (100 mg/day) or placebo over a six-month treatment period.
Results
Atotal ofl4l 
Conclusion Amisulpride iseffective in
the medium-term treatment of schizo phrenic patients with predominantly nega tive symptoms.
It is currently accepted that negative symp toms in schizophrenia are heterogeneous. A clinically relevant distinction can be made between primary negative symptoms, which are part of the disease process, and secondary negative symptoms due to other factors (Carpenter et a!, 1988) . The impor tant question of whether primary negative symptoms or deficit symptoms respond to neuroleptic agents is currently under discus sion (Carpenter et a!, 1995; Meltzer, 1995) . Neurochemical evidence suggests that these symptoms could be related to decreased dopaminergic function (Kahn & Davis,
1995).
Amisulpride is a substituted benzamide with high selectivity for dopamine D2 and D3 receptors, preferentially in the limbic system rather than the striatum. It has no affinity for other receptors. Furthermore, it preferen tially blocks presynaptic dopamine autore ceptors at low doses, whereas at higher doses (like the standard neuroleptics) it also blocks post-synaptic dopamine receptors. These properties could explain the pharmacolo gical profile ofamisulpride in animal models, indicating activating properties at low doses and an absence of catalepsy even at high doses (Scatton et a!, 1995) . This atypical profile may account for the clinical efficacy on positive symptoms of schizophrenia at high doses and on negative symptoms at low doses, and its low propensity to induce extrapyramidal side-effects (foyer et a !, 1990; Hillert et al, 1994; MÃ ¶ller et a!, 1996; Puech et a!, 1996) . In two short-term (six-week), placebo-controlled studies (SO 300 mg/day), in patients with predominantly negative symptoms, amisulpnde produced significant improvement in mean Scale for the Assessment of Negative Symptoms (SANS; Andreasen, 1984a) scores (Boyer et a!, 1995; PaillÃ¨re-Martinot et a!, 1995 Routine blood tests were performed both before the study and at the end.
Analysis
Statistical analysis was performed on an intention-to-treat basis, including all rando mised patients who had at least one available treatment evaluation. Bilateral tests were used with a significance level of a=O.OS. One-way analysis of variance (treatment group) was performed for the comparison of the efficacy variables. Non-parametric tests (Kruskalâ€"Wallis, Cochran, Mantel Haenszel and Fisher's exact probability tests) were used when appropriate.
RESULTS
Patients
One hundred and forty-one patients, 100 males (71%) and 41 females (29%), mean age 34 Â± 10 years, with a mean duration of illness of 10 Â± 9 years, were enrolled into the study. The majority of the patients (55%) were of the residual type, and 116 (82%) had chronic illness ( > 2 years duration). The patients' demographic and disease character istics are shown in Table 1 .
The proportion of patients treated with
neuroleptics before entering the study was similar in both groups: 28 patients (39%) in the placebo and 30 (43%) in the amisulpride group had received neuroleptics in the month before entering the study; seven placebo patients and eight amisulpride patients had received concomitant anti Parkinsonian medication prior to enrolment.
Treatment discontinuation
After three months of treatment the drop-out rate was significantly lower (P< 0.002) in the amisulpride group (29%) than in the placebo group (57%). This trend persisted after six months (45 and 68% drop-out, in the amisulpride and placebo groups, respec tively; P< 0.007). The main reason for discontinuation was lack of efficacy (see Table 2 ). Worsening of either positive or negative symptoms was assessed at the time of drop-outfor patientswithdrawingprema rarely for inefficacy. An increase in SAPS to a total score of > SO was considered indicative of productive relapse (a score of @ SO was used to exclude productive patients); a I, % oftreatment group.
2. %oftotal drop-outs withinthetreatmentgroup.
Patients discontinuing for â€˜¿ lack ofefficacy' plus â€˜¿ lostto follow up' versus the rest ofthe total group sample. Scores on the SAPS scale remained low throughout the trial, with no significant differences between the two groups (Table  3) . Efficacy results were maintained over time; of the amisulpride patients, 27 of the 28 responders at three months remained responders at the trial's conclusion.
Forty-one patients (59%) in the amisulpride group and 33 (46%) in the placebo group experienced at least one adverse event. In the amisulpride group, the most common events were: sleep disorder (eight), weight increase (six), anxiety (four), nervousness (four) and amenorrhoea (four of the 23 female patients). In the placebo group the most common adverse events were: sleep disorder (eight), tremor (seven), anxiety (six), head ache (five), weight decrease (five), vomiting (four) and nausea (four). One patient (1.4%) in the amisulpride group and five (7%) in the placebo group dropped out because of adverse events. A significant mean increase (1.4 kg) in body weight was observed in the amisulpride patients, whereas a mean decrease of 0.8 kg occurred in the placebo group (P<0.013). There were no clinically relevant findings with regard to the physical or laboratory examinations.
Safety
I. An increase in GAF score represents an improvement.
2. Scoreon leavingtrial v.initialscoreinamisulpride group. 3. Meanimprovement aspercentage changeinscoreinamisulpride v.placebogroups. similar number of patients discontinued for relapse (four and five patients in the amisulpride and placebo groups, respec tively). Mean SANS total scores of those patients who dropped out of the study were close to those assessed at baseline (78.5 Â± 17.7 and 75.9 Â± 23.3 in the amisul pride and placebo drop-outs, respectively).
Efficacy
Amisulpride showed significantly (P<0.000S) greater improvement in the SANS total score on completion of the trial compared with placebo (Table 3) . Mean improvement (as a percentage of the score at baseline) was 41 v. 20% in the amisulpride and placebo groups, respectively (P<0.0002; Table 3 ). Significant differences (at levels ranging from P< 0.02 to P< 0.0002) in favour of amisulpride were also found for all five SANS component subscores (Table 4) . Responders, defined as having an improvement of at least 50% of their SANS baseline total score, were significantly more frequent in the amisulpride group than in the placebo group (42 v. 15.5%, respec tively; P<0.O01).
When response was defined by the CGI (items 2 â€˜¿ very much' or â€˜¿ much improved'), similar results were obtained: 46% of those on amisulpride were responders compared with 19% of those on placebo (P < 0.004). Responders had a mean improvement in their SANS total score of 67% in the amisulpride group and 60% in the placebo group, which confirms that the global measure of response corresponds to improvement in negative symptoms. Of the 14 patients who improved on placebo, five received neuroleptics during the month prior to inclusion. This corresponds to the proportion of patients with neuroleptic pre-treatment in the total group and does not suggest that placebo â€˜¿ response' was an effect due simply to neuroleptic wash-out.
The GAF scale also showed significant improvement in the amisulpride compared with the placebo group (P<0.03; Table 3 ). 
Neurological side-effects
In addition to the 15 patients (seven in the placebo group, eight in the amisulpride group) who received anti-Parkinsonian drugs prior to enrolment, and for whom treatment was not discontinued, anti-Parkin sonian treatment was initiated in five patients (one in the placebo group, four in the amisulpride group) during the study.
Extrapyramidal symptoms (Webster scale) were mild at baseline, with mean (standard deviation) scores of 3.8 (5) and 3.1 (3) in the amisulpride and placebo groups, respec tively. On leaving the study, the mean scores were 2.4 (4) in both groups. Scores for akathisia (Barnes scale) were similarly low at inclusion and remained stable throughout the trial. On leaving the trial, 10 patients in the amisulpride group and six who had received placebo had doubtful-to moderate akathisia, while one patient on placebo was rated as having severe akathisia. No significant difference was found on final akathisia scores between the treatment groups. Scores on the AIMS also were low at baseline, with mean (standard deviation) scores of 2.2 (4.8) and 1.2 (2.4) in the amisulpride and placebo groups, respec tively. On leaving the study, mean scores were 1.4 (3) and 1.3 (2.7), respectively. and occupational changes. The fact that 19% of placebo-treated patients also responded is surprising and is not explained by neuroleptic wash-out. It probably corre sponds to a non-specific effect related to study participation.
There are some limitations concerning the interpretationof the study results.First, about 40% of patients in each group received neuroleptics prior to enrolment and, even though the study treatment lasted for six months, it cannot be excluded that the improvement in negative symptoms was partly due to a wash-out effect of previous neuroleptics, although this would not explain the difference in efficacy between the two groups. The same is true for the prescription of anticholinergic drugs. Second, the higher rate of drop-outs in the placebo group could have biased the efficacy comparison in favour of amisulpride, or it could simply mean that more patients on placebo had acute produc tive relapses. However, the latter assumption is not supported by the end-point assess mentsof the drop-outs,wherea similarlylow proportion in both groups discontinued because of acute relapses. Furthermore, the SANS mean scores at discontinuation were near the baseline levels, indicating that discontinuation was mainly due to lack of efficacy on negative symptoms.
CONCLUSIONS
The patient selection, together with improve ment of negative symptoms independent of concomitant changes in Parkinsonism and positive symptoms, indicate a positive effect of low doses of amisulpride on core (primary) negative symptoms. This effect must be distinguished from that of higher doses of the drug on secondary negative symptoms in studies including patients with predominantly productive symptoms (MÃ ¶ller et a!, 1996; Puech et a!, 1996) .
Amisulpride was well tolerated, with a safety profile, concerning anxiety and insomnia, not notably different from placebo. As expected, endocrine disturbances and weight gain were more frequent with amisuipride. The results of the present study are consistent with previous results, and confirm that amisulprideis effective in the medium-termtreatment of schizophre nics with predominantly negative symptoms.
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DISCUSSION
Study sample
Although information on the previous history of the patients is limited, the fact that more than 80% had a chronic course and the majority were of the residual type suggests that negative symptoms were stable before entering the study. Furthermore, positive symptoms and symptoms of Parkinsonism were low at baseline and did not change substantially during treatment, indicating that the negative symptoms were mainly primary and not due to positive or extra pyramidal symptoms.
Studyresults
Both global response rates and improvement on the SANS and its subscores gave consistent results, showing a significant improvement in negative symptoms with amisulpride compared with placebo. The response rate (CGI) also was significantly higher in the amisulpride group. Those results were confirmed by the significant improvement in the global functioning measured with the GAF, which gives further information on psychological, social
